Global Infectious Disease Therapeutics Market 2022-2028
About this market
Development of novel drugs to drive growth in the market. There has been an increase in the R&D of novel drugs for the treatment of infectious diseases. The analysts have predicted that the infectious disease therapeutics market will register a CAGR of over 4% by 2023.
Market Overview
Increasing prevalence of infectious diseases
There has been an increase in the prevalence of infectious diseases due to climate variability. This is expected to be a major driver of the market growth during the forecast period.
Availability of counterfeit drugs
Counterfeit drugs are available in low-income and developing countries. These drugs are widely available because of insufficient regulations and manufacturing control.
For the detailed list of factors that will drive and challenge the growth of the infectious disease therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Merck and Sanofi the competitive environment is quite intense. Factors such as the development of novel drugs and the increase in the prevalence of infectious diseases, will provide considerable growth opportunities to infectious disease therapeutics manufactures. AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi are some of the major companies covered in this report.
Development of novel drugs to drive growth in the market. There has been an increase in the R&D of novel drugs for the treatment of infectious diseases. The analysts have predicted that the infectious disease therapeutics market will register a CAGR of over 4% by 2023.
Market Overview
Increasing prevalence of infectious diseases
There has been an increase in the prevalence of infectious diseases due to climate variability. This is expected to be a major driver of the market growth during the forecast period.
Availability of counterfeit drugs
Counterfeit drugs are available in low-income and developing countries. These drugs are widely available because of insufficient regulations and manufacturing control.
For the detailed list of factors that will drive and challenge the growth of the infectious disease therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Merck and Sanofi the competitive environment is quite intense. Factors such as the development of novel drugs and the increase in the prevalence of infectious diseases, will provide considerable growth opportunities to infectious disease therapeutics manufactures. AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi are some of the major companies covered in this report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
